Patent SG-11201807965Y-A (SG)
Title: Combinations of lsd1 inhibitors for use in the treatment of solid tumors
Inventor: DEMARIO MARK
IPC: A61K31/4045
Filed: 2017-03-13
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization M1111101110101011111 HO 11111 01E3 100 111110101110 11n III 11 International Bureau 0.. .... .. (10) International Publication Number ..... ..or::,„, (43) International Publication Date WO 2017/157825 Al 21 September 2017 (21.09.2017) WIP0 I PCT (51) International Patent Classification: Life Science, New York, NY 10016 (US). MAES, A61K 31/12 (2006.01) A61K 31/475 (2006.01) Tamara; c/o Oryzon Genomics S.A., C. Sant Ferran 74, A61K 31/135 (2006.01) A61K 31/495 (2006.01) 08940 Cornelia de Llobregat (ES). LUNARDI, Serena; A61K 31/19 (2006.01) A61K 31/519 (2006.01) c/o Oryzon Genomics S.A., C. Sant Ferran 74, 08940 Cor- A61K 31/282 (2006.01) A61K 31/555 (2006.01) nella de Llobregat (ES). A61K 31/337 (2006.01) A61K 31/704 (2006.01) A61K 31/4045 (2006.01) A61K 31/7068 (2006.01) (74) Agent: MUELLER-AFRAZ, Simona; Grenzacherstrasse A61K 31/4745 (2006.01) A61P 35/00 (2006.01) 124, 4070 Basel (CH). (21) International Application Number: (81) Designated States (unless otherwise indicated, for every PCT/EP2017/055784 kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (22) International Filing Date: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, 13 March 2017 (13.03.2017) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (25) Filing Language: English HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, (26) Publication Language: English MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (30) Priority Data: RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, 62/308,529 15 March 2016 (15.03.2016) US TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (71) Applicant (for all designated States except US): F. HOFF- ZA, ZM, ZW. MANN-LA ROCHE AG [CH/CH]; Grenzacherstrasse (84) Designated States (unless otherwise indicated, for every 124, 4070 Basel (CH). kind of regional protection available): ARIPO (BW, GH, Applicant (for US only): HOFFMANN-LA ROCHE GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, INC. [US/US]; Overlook at Great Notch, 150 Clove Road TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, 8th Floor, Suite 8 - Legal Department, Little Falls, NJ TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, 07424 (US). DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, (71) = (72) Inventors: DEMARIO, Mark; c/o Roche TCRC, Inc. East SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, 29th Street, Alexandria Center for Life Science, New York, GW, KM, ML, MR, NE, SN, TD, TG). = = NY 10016 (US). PIERCEALL, William; c/o Roche TCRC, Inc. East 29th Street, Alexandria Center for Life Published: — — Science, New York, NY 10016 (US). MACK, Fiona; c/o — with international search report (Art. 21(3)) Roche TCRC, Inc. East 29th Street, Alexandria Center for = = = = = = = Il kin ei cc IN kin ,-1 IN ,-1 © (54) Title: COMBINATIONS OF LSD1 INHIBITORS FOR USE IN THE TREATMENT OF SOLID TUMORS ei 0 (57) : The instant invention relates to therapeutic combinations of LSD1 inhibitors and one or more other active pharma- ceutical ingredient(s) or pharmaceutically acceptable salts thereof. The combinations are particularly useful for treating neoplastic diseases, such as cancer, particularly small cell lung cancer (SCLC).